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Abstract
Background: Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4
+ T-cells caused by human T-cell
leukemia virus type 1 (HTLV-1). The HTLV-1 bZIP factor (HBZ) gene, which is encoded by the minus strand of the
viral genome, is expressed as an antisense transcript in all ATL cases. By using yeast two-hybrid screening, we
identified activating transcription factor 3 (ATF3) as an HBZ-interacting protein. ATF3 has been reported to be
expressed in ATL cells, but its biological significance is not known.
Results: Immunoprecipitation analysis confirmed that ATF3 interacts with HBZ. Expression of ATF3 was upregulated
in ATL cell lines and fresh ATL cases. Reporter assay revealed that ATF3 could interfere with the HTLV-1 Tax’s
transactivation of the 5’ proviral long terminal repeat (LTR), doing so by affecting the ATF/CRE site, as well as HBZ.
Suppressing ATF3 expression inhibited proliferation and strongly reduced the viability of ATL cells. As mechanisms
of growth-promoting activity of ATF3, comparative expression profiling of ATF3 knockdown cells identified
candidate genes that are critical for the cell cycle and cell death, including cell division cycle 2 (CDC2) and cyclin
E2. ATF3 also enhanced p53 transcriptional activity, but this activity was suppressed by HBZ.
Conclusions: Thus, ATF3 expression has positive and negative effects on the proliferation and survival of ATL cells.
HBZ impedes its negative effects, leaving ATF3 to promote proliferation of ATL cells via mechanisms including
upregulation of CDC2 and cyclin E2. Both HBZ and ATF3 suppress Tax expression, which enables infected cells to
escape the host immune system.
Background
Adult T-cell leukemia (ATL) is an aggressive CD4
+ T-
cell malignancy caused by human T-cell leukemia virus
type 1 (HTLV-1) [1-5]. In the plus strand of its genome,
HTLV-1 encodes the regulatory proteins Tax and Rex
and the accessory proteins p12, p30, and p13. The
HTLV-1 basic leucine zipper factor (HBZ)g e n ei s
expressed as an antisense transcript. It has been
reported that HBZ is consistently expressed and remains
intact in all ATL cases and HTLV-1-infected individuals
[6,7], where it promotes cell proliferation [6,8].
The HBZ gene is expressed as two isoforms: spliced HBZ
(sHBZ) and unspliced HBZ (usHBZ) [9-12]. The expres-
sion of sHBZ in T-cells promotes T-cell proliferation
whereas that of usHBZ does not [8,12]. HBZ was reported
to repress Tax-mediated transactivation of viral transcrip-
tion from the HTLV-1 promoter by dimerizing with
transcription factors including cyclic AMP response ele-
ment-binding protein 2 (CREB2), and members of the Jun
family [10,13-16]. HBZ also promotes the degradation,
directly and without ubiquitination, of some proteins that
interact with HBZ [17]. Thus, HBZ interacts with host
factors and modulates their function, which is likely to
contribute to persistent infection of HTLV-1 in vivo and
clonal expansion of infected cells.
Activating transcription factor 3 (ATF3) is a member of
the ATF/cyclic AMP response element-binding (CRE)
family of transcription factors [18]. ATF3 is an adaptive
response gene whose expression is regulated by changes
in the extra- or intracellular environment. ATF3 activates
signals including DNA damage [19], anoxia [20], hypoxia
[21], and represses others, including inflammation [22].
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lar bZIP transcription factors, including ATF2, c-Jun,
JunB, and JunD, and exerts pleiotropic functions through
ATF/CRE and AP-1 sites depending on cell type. It has
also been pointed out that the ATF3 gene has a potential
dichotomous role in cancer development [23]: it has pro-
apoptotic functions, like a tumor suppressor, but at the
same time induces cell proliferation, like an oncogene. It
has been reported as up-regulated in malignant breast
cancer cells [23], Hodgkin cells [24], and prostate cancer
cells [25] where it is associated with proliferation. Trans-
g e n i cm i c eo v e r e x p r e s s i n gA T F3 in basal epithelial cells
develop basal cell carcinomas [26]. Up-regulation of
ATF3 is also reported in ATL cells [27], yet the biological
significance in ATL is not known. Moreover, the ques-
tion of how ATF3 induces proliferation of cancer cells
remains unsolved.
In the process of elucidating the function of sHBZ in
T-cells [6,12,28], we identified ATF3 as a sHBZ-interact-
ing protein. In this study, we characterized the role of
ATF3 in ATL cells. ATF3 was constitutively expressed
in ATL cell lines and fresh ATL cases. ATF3 could
repress Tax-mediated transactivation through ATF/CRE
sites. Expression of ATF3 was linked to proliferation of
ATL cells via upregulation of cell cycle-associated genes
and down-regulation of proapoptotic genes. Further-
more, while ATF3 alone enhanced p53 stability, and
therefore activation; sHBZ inhibited this function.
Results
Identification of ATF3 as a sHBZ interacting protein
We employed a yeast two-hybrid system with sHBZ as
bait, to identify potential binding partners for sHBZ.
Human activated mononuclear cell RP1 libraries were
used for this screening and several candidates were
identified (data not shown). Among them, we focused
on ATF3 for the following reasons: First, ATF3 was
reported to play a role in both survival and proliferation
of cancer cells [25,29-31]. Second, ATF3 transcript is
expressed in ATL cells [27] although little is known
about the biological significance of this expression, in
particular whether expression of ATF3 is associated
with ATL cell proliferation [27]. Third, the relation
between ATF3 and HTLV-1 viral transcription is
unknown. Immunoprecipitation analysis demonstrated
that sHBZ and ATF3 interacted when transfected in
mammalian cells (Figure 1). By using a series of trun-
cated proteins, we found that bZIP domains of both
sHBZ and ATF3 are necessary for their interaction.
The ATF3 promoter is constitutively activated in ATL cell
lines
Next, we checked the expression level of ATF3 mRNA
and protein in ATL cell lines. The ATF3 gene has two
promoters: a non-canonical alternative promoter P1 and
the canonical promoter P2 (Figure 2A) [32,33]. RT-PCR
analysis demonstrated that all ATL cell lines constitu-
tively expressed the ATF3 P1 and P2 transcripts
(Figure 2B). ATF3 protein expression was also detected
in all ATL cell lines (Figure 2B). In addition, all ATL
cell lines expressed the sHBZ gene transcript while the
tax gene was transcribed in only some ATL cell lines,
consistent with earlier reports (Figure 2B) [6]. Although
these data suggested that sHBZ expression might be
associated with increased ATF3, ectopic expression of
sHBZ did not induce ATF3 gene transcription in Jurkat
cells (data not shown). Immunohistochemical analysis of
lymph nodes of ATL patients showed that lymphoma
cells indeed expressed ATF3 (Figure 2C).
Suppressive effects of ATF3 on cellular and viral ATF/CRE
sites
It has been reported that Tax activates the transcription
of the plus strand of HTLV-1 as well as influencing host
cellular gene transcription. Tax transcription of HTLV-1
genes depends on ATF/CRE-like sequences (viral CRE)
in the U3 region of the HTLV-1 LTR [34,35]. ATF3, on
the other hand, is reported to repress transcription from
cellular ATF/CRE sites [36]. Based on these findings, we
investigated whether ATF3 could influence Tax-
mediated transcription. pCRE × 4-luc is a reporter con-
struct containing a cellular ATF/CRE consensus
sequence, while WT-luc contains ATF/CRE-like
sequences from the HTLV-1 LTR. These plasmid DNAs
were used to study the effect of ATF3 on transcription
through cellular and viral CREs. Tax could activate the
cellular and viral CRE reporters, but ATF3 by itself did
not influence their activity (Figure 3A and 3B). ATF3
inhibited Tax-mediated transcription from ATF/CRE
and viral CRE sites in a dose-dependent manner (Figure
3A and 3B). sHBZ also repressed Tax-mediated tran-
scription, as reported previously [10]. When ATF3 and
sHBZ were co-expressed, sHBZ did not inhibit the
repressive function of ATF3. Next we checked the effect
of ATF3 on Tax-mediated viral transcriptional activity.
A reporter construct containing the entire HTLV-1
5’LTR was activated by Tax, as expected (Figure 3C).
ATF3 repressed this transcription (Figure 3C). sHBZ
also repressed Tax-mediated activation of this reporter,
without interfering with the suppressive function of
ATF3. These results suggest that ATF3 suppresses Tax-
mediated ATF/CRE-dependent transcription both of cel-
lular genes and the HTLV-1 LTR.
ATF3 has growth promoting activity in ATL cells
To investigate the functional significance of ATF3
expression in ATL cells, we transfected MT-4 and ED
cells with lentiviral vectors expressing three different
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strongly suppressed ATF3 protein expression shown in
Figure 4A. An MTT assay showed that knockdown
(KD) of ATF3 resulted in reduced proliferation of both
Tax expressing MT-4 cells and Tax non-expressing ED
compared to control cells (Figure 4B). Cell cycle analysis
revealed that the population of G1 cells increased, while
the population of cells in S phase decreased in ATF3
KD MT-4 cells (Figure 4C). KD of ATF3, then, impaired
the G1/S transition in MT-4 cells, and hence ATF3
expression in ATL cell lines was associated with their
proliferation.
Transcriptional profile of ATF3 KD MT-4 cell
To find mechanisms by which ATF3 might increase
proliferation, we performed oligonucleotide microarray
analyses of ATF3-KD MT-4 cells and MT-4 cells trans-
duced with a control vector. We compared the data
from the negative control and ATF3-KD cells, and out
of 18,400 transcripts, we first identified 2188 genes
whose transcription changed more than two fold by KD.
Of these, 1522 genes were up-regulated, and 658 down-
regulated in ATF3-KD cells. Representative genes that
were up-regulated or down-regulated by ATF3 are
shown in Figure 5A and additional file 1.
We confirmed the expression of several up-regulated
genes by RT-PCR to validate the results of the DNA
microarray (Figure 5B). Suppressed expression of
ATF3 increased the number of transcripts of proapop-
totic genes, Bim and Harakiri.I nc o n t r a s t ,c e l ld i v i -
sion cycle 2 (CDC2) and cyclin E2 (CCNE2), which
control the cell transition from G1 phase to S phase
[37], were down-regulated in ATF3-KD cells. This is
the first report that ATF3 affects the expression of
these genes.
CDC2 is a direct target of ATF3
Since KD of ATF3 impairs the G1/S transition, we
focused on cdc2 and ccne2 gene expression. Quantitative
analysis by real-time PCR confirmed that transcription of
both the cdc2 and ccne2 genes was down-regulated in
ATF3 KD cells compared to control cells (Figure 5C).
The cdc2 gene expression was significantly decreased by
KD of ATF3, so cdc2 gene was chosen for further studies.
T os t u d yw h e t h e rt h ee f f e c to fA T F 3o nt h ecdc2 gene is
direct or indirect, we investigated the binding of ATF3 to
the promoter region of the cdc2 gene (Figure 5D). This
region contains two putative binding sites for ATF3, an
AP-1 site near the transcription start site, and an ATF/
CRE site farther 5’-ward (Figure 5D). A chromatin
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Figure 1 Domains of ATF3 and sHBZ responsible for their interaction. (A) Determination of the region of ATF3 responsible for the
interaction with HBZ. 293FT cells were transfected with a FLAG-ATF3 mutant lacking the zipper domain along with sHBZ-Myc-His. 48 hours after
transfection, total cell lysates were subjected to IP using anti-FLAG followed by IB using anti-His. (B) The region of HBZ responsible for interaction
with ATF3. 293FT cells were transfected with the indicated tagged-HBZ mutants along with the FLAG-ATF3 vector. Cell lysates were subjected to
IP using anti-Myc followed by IB using anti-FLAG. Schematic diagrams of ATF3 (A) and HBZ (B) are shown. AD, activation domain; RD, repression
domain; LZ, leucine zipper; CD, central domain; WT, wild type. Asterisk (* or **) shows the region responsible for the molecular interaction.
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proximal AP-1 site, but ATF3 bound to ATF site was
non-specific (Figure 5E). Transient transfection of Jurkat
T cells by electroporation with a vector expressing ATF3
up-regulated the expression of cdc2 mRNA (Figure 5F).
These results indicate that ATF3 directly activates tran-
scription of the cdc2 gene.
sHBZ inhibited the augmentation of p53 transcriptional
activity by ATF3
In addition to its oncogenic function, ATF3 is also
reported to augment transactivation of p53 responsive
promoters in a non-small cell lung carcinoma cell line
by protecting p53 from ubiquitin-associated degradation
[31,38]. Expression of ATF3 in ATL cells therefore has
A
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Figure 2 Constitutive expression of ATF3 in ATL cells. (A) Schematic diagram of the primers (arrowhead) for detecting transcripts from P1
and P2 promoters of the ATF3 gene. Square boxes represent the exons and white boxes represent open reading frame (ORF). Two distinct ATF3
transcripts that encode the same ORF are reported[32]. (B) ATF3 mRNA from P1 and P2 transcripts in HTLV-1 infected cell lines and ATL cell lines
was determined by RT-PCR. Expression of ATF3 protein was studied by immunoblot (IB). Lane 1, Molt4; lane 2, CEM: lane 3. Kit225; lane 4, Jurkat;
lane 5, ATL2; lane 6, ATL-43T; lane 7, ED; lane 8, TL-Om1; lane 9, MT-1; lane 10, MT-2; lane11, MT-4. (C) Immunostaining for ATF3 in lymph nodes
of an ATL patient.
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Page 5 of 12the potential to promote apoptosis through p53, since
mutations of p53 are rare in ATL cases [39]. To explore
this possibility, we checked the ability of ATF3 to aug-
ment p53 transcriptional activity in T-cells. A reporter
assay showed that, as reported previously [31,38], ATF3
enhanced transcriptional activity of p53 in ZIP domain
dependent manner (Figure 6A and 6B). sHBZ, though it
had no influence on p53 transcriptional activity itself,
suppressed the increased transcriptional activity of p53
by ATF3 (Figure 6A). Analyses using sHBZ deletion
mutants showed that the bZIP domain and the central
domain of sHBZ were responsible for the suppressive
activity (Figure 6B). To investigate how sHBZ reduces
ATF3’s ability to enhance p53 transcriptional activity,
immunoprecipitation analyses were performed
(Figure 6C). ATF3 interacted with p53 but sHBZ reduced
this interaction. Serial immunoprecipitation experiments
demonstrated that sHBZ, ATF3 and p53 were present in
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Figure 3 Suppressive effects of ATF3 on Tax-mediated transactivation through ATF/CRE sites. Jurkat cells were cotransfected with phRL-
TK and expression vectors for ATF3, HBZ, and reporter plasmid pCRE × 4-luc (A), WT-luc (B), or LTR-luc (C) respectively. The total amount of DNA
for transfection was equalized by adding empty vectors. After 24 hours, a dual luciferase reporter assay was performed as described in Materials
and Methods. All the data are relative values of firefly luciferase normalized to Renilla luciferase and shown as a mean of a triplicate set of
experiments (mean ± SD). *P< 0.05; **P< 0.01.
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binds directly to ATF3-p53 complexes; that this binding
interferes, by unknown mechanisms, with ATF3
enhancement of p53 signaling; and that ATL cells expres-
sing sHBZ can thereby escape the apoptosis that ATF3
expression might otherwise induce.
Discussion
In this study, a yeast two-hybrid system identified ATF3
as a binding partner of the HTLV-1 sHBZ protein.
Aberrant expression of ATF3 has been reported in clas-
sical Hodgkin lymphoma (cHL) and malignant prostate
cancer cell [24,25], where it is associated with increased
proliferation. In addition, increased expression of ATF3
was also reported in ATL cases [27]. However, the
mechanism by which ATF3 promotes proliferation of
cancer cells remained unknown. In this study, we
demonstrated that increased expression of ATF3 was
linked to proliferation via enhanced transcription of the
cdc2 and ccne2 genes, along with suppressed expression
of proapoptotic factors including Harakiri, and Bim.
ATF3 indeed bound to the promoter region of the cdc2
gene and enhanced its transcription. Thus, ATF3 modu-
lates transcription of cellular genes associated with pro-
liferation and apoptosis.
ATF3 has been reported to act as transcriptional
repressor of ATF/CRE sequences. In this study, we
found that ATF3 suppressed activation, by the viral fac-
tor Tax, of transcription from CRE-like sequences in the
5’LTR. Tax, itself transcribed from the 5’LTR, is a major
target of cytotoxic T-lymphocytes in vivo [40]. There-
fore, suppression of tax gene transcription could benefit
the survival of ATL cells, by allowing them to escape a
cytotoxic T-lymphocyte response. In contrast to the tax
gene, ATL cells need to express the HBZ gene tran-
scripts for their proliferation [5]. HBZ is transcribed
from the 3’LTR, and therefore unaffected by ATF3 sup-
pression of the 5’LTR. By suppressing viral gene
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Figure 4 Knockdown of ATF3 by shRNA impairs proliferation of ATL and HTLV-1 infected cells. MT-4 and ED cells were transduced with
lentivirus vector expressing control and ATF3-directed shRNA. (A) ATF3 protein was determined by immunoblot. (B) The cell growths of ATF3
knock-down ATL cells by shRNAs were measured by MTT assay. (C) The effect of ATF3 KD using ATF3_KD1 on cell cycle progression was
analyzed by PI staining in MT-4 cells. Five days after infection, cells were analyzed by a flow cytometry as described in the Materials and
Methods.
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Page 7 of 12transcription through the 5’LTR, then, ATF3 modulates
viral gene expression, favoring expression of the HBZ
gene over the tax gene. Enforced expression of ATF3 in
prostate cancer cells induces cell proliferation and accel-
erates progression from the G1- to S-phase of the cell
cycle [25]. The same study also showed that KD of
ATF3 expression decreased cells in S phase while it
increased cells in G1 phase [25]. In addition, impaired
G1/S transition in c-myc null cells was partially recov-
ered by ATF3 expression [30], indicating the role of
ATF3 in G1/S transition.
In this report, we present evidence that the expression
of ATF3 is associated with G1/S progression via
enhanced transcription of the cdc2 and ccne2 genes, and
possibly others. In particular, ATF3 bound the CDC2
promoter directly. The cdc2 gene plays a key role in the
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Figure 5 CDC2 is a direct target of ATF3. (A) The ratios of transcripts (Control/ATF3 KD populations) of 12 genes related to the cell cycle or
apoptosis in the 2 groups are plotted. Open circles represent the up-regulated genes and black lozenges show the down-regulated genes. (B)
The level of mRNA was studied by semi-quantitative RT-PCR to confirm the result of microarray analysis. (C) Control and ATF3 KD cells were
analyzed by real-time PCR for the indicated mRNA. The expression level of control cells was defined as 1. Mean ± SD was based on results of
three independent experiments (P < 0.01). (D) Schematic diagram of CDC2 primer used for ChIP assay. (E) 293FT cells were transfected with
ATF3 expression vector. 48 hours after transfection, chromatin was prepared for a ChIP assay using an anti-ATF3 antibody. Anti-IgG was used as a
negative control. (F) Jurkat cells were transiently transfected with ATF3 expression vector and CDC2 mRNA expression was measured by real-time
PCR.
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Page 8 of 12transition from the G1 phase to the S phase [41], and
from the G2 phase to the M phase. The ccne2 gene is
reported to be highly expressed in a number of human
primary tumors including breast, ovary, uterus, brain,
and lung [42]. Our results now open the possibility that
ccne2, as well as cdc2, may contribute to ATL as well.
Independent of its cell cycle-promoting function,
ATF3 also acts like a tumor suppressor, enhancing p53
transcriptional activity by inhibiting its ubiquitin-
mediated degradation [31,38]. ATF3 neither interferes
with the p53-MDM2 interaction nor blocks the E3 ligase
activity of MDM2, suggesting that binding of ATF3 to
p53 likely induces a conformational change of p53 that
inhibits ubiquitination [31,38]. Since ATF3 is an adap-
tive response gene that responds to extra or intracellular
changes, ATF3 stabilization of p53 counters cellular
stress due to environmental insult and ensures genomic
integrity [31,38]. Given that p53 is mutated in only
about 30% of ATL cases [43-45], and in fact the expres-
sion level of p53 protein increases in ATL cells [46],
how is ATF3’s p53-stabilizing activity consistent with
the chromosome instability often observed in ATL cells
[47]? In fact, post-translational inactivation of p53 is cri-
tical to understanding ATL development. A viral pro-
t e i n ,T a x ,c a nf u n c t i o n a l l yinactivate p53 by competing
for binding to E-box [48], as well as other mechanisms
[49]. However, Tax is not expressed in many ATL cases,
due to genetic and epigenetic changes of the HTLV-1
provirus [5,50], including nonsense mutations generated
by APOBEC3G [51]. Mechanisms other than Tax must
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Figure 6 HBZ inhibits the augmentation of p53 transcriptional activity by ATF3. (A, B) Jurkat cells were cotransfected with phRL-TK and
reporter plasmid pG13-luc and expression vectors for p53, ATF3 and HBZ or their deletion mutants. After 24 hours, a dual luciferase reporter
assay was preformed. All the data shown are relative values of firefly luciferase normalized to Renilla luciferase and shown as the mean of a
triplicate set of experiments (mean ± SD). *P< 0.05; **P< 0.01. (C, D) 293FT cells were transfected with p53, FLAG-ATF3, and sHBZ-Myc-His
expression vectors. (C) Total cell lysates were subjected to IP using anti-FLAG followed by IB using anti-His and anti-p53. (D) Total cell lysates
were subjected to a first IP step using anti-FLAG antibody. Immunocomplexes were eluted from anti-FLAG antibody-conjugated beads with
FLAG peptide and then subjected to a second IP step using anti-Myc followed by IB using anti-p53.
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study, sHBZ binds to ATF3-p53 complexes. With these
interactions, sHBZ reduces ATF3’s ability to enhance
p53 function. HTLV-1 is not unique in deploying viral
proteins to perturb p53 function. The latency-associated
nuclear antigen encoded by Kaposi’s sarcoma-associated
herpesvirus, for example, binds to von Hippel-Lindau
factor and targets it for degradation[52]. The human
papilloma virus-encoded E6 protein binds to the cellular
E6-associated protein (E6AP), an ubiquitin ligase that
targets p53 for destruction. In fact, this interaction is
blocked by ATF3, revealing another way in which ATF3
reinforces p53 signaling [53].
In HTLV-1’s case, sHBZ perturbs one ATF3 function -
p53 stabilization - that might slow the proliferation of
infected cells, while leaving other functions - promotion
of G1/S transition, and repression of provirus transcrip-
tion - unaffected. HTLV-1 reproduces mainly by promot-
ing the clonal expansion of infected cells, rather than by
producing new virus particles. As such, the potential ben-
efits to the virus of modulating ATF3 function in this way
are clear: ATF3, in combination with sHBZ, encourages
infected cells to progress through the G1/S phase transi-
tion, unimpeded by a ATF3-p53 response, and free from
detection by host immune cells that might recognize viral
antigens transcribed from the 5’LTR.
Conclusions
This study reveals a role of ATF3 in regard to prolifera-
tion and viral gene transcription in ATL cells. The com-
bined effects of ATF3 and sHBZ allow ATL cells to
survive in vivo, and could be a target of therapy for this
malignant disease.
Methods
Cell lines
All T-cell lines and ATL cell lines were grown in RPMI
1640 supplemented with 10% fetal bovine serum and
antibiotics. 293FT cells were cultured in Dulbecco modi-
fied Eagle medium supplemented with 10% FBS and
500 μg/ml G418.
Yeast two-hybrid
A yeast two-hybrid screen was performed by Hybri-
genics (http://www.hybrigenics.com) on a random-
primed Leukocytes and Activated Mononuclear Cells
cDNA library using HBZ as bait.
Plasmids
The ATF3 coding sequence was amplified by polymer-
ase chain reaction (PCR) and was cloned into pCMV-
Tag2 (Stratagene, La Jolla, CA), or pcDNA3 (Invitrogen,
Carlsbad, CA). Expression vectors for sHBZ [28], its
deletion mutants [28], reporter plasmids pWT-luc,
pLTR-luc [34,35], and pG13-luc [54] were described
previously. pCREx4-luc was purchased from Stratagene
( L aJ o l l a ,C A ) .L u c i f e r a s ea s s a yw a sp e r f o r m e da s
described previously [12].
Knockdown analysis
Cells were infected with an shRNA lentiviral vector
(Invitrogen) directed against ATF3. The following target
sequence were chosen: ATF3_KD1 5’-GAGCTGAG-
GTTTGCCATCC-3’,A T F 3 _ K D 25 ’-GTGTATTGTC-
CGGGCTCAG-3’ and ATF3_KD3 5’-GAACGAGAA
GCAGCATTTG-3’ as described previously [24]. Control
cells were infected with an shRNA retroviral vector
expressing a nonsilencing construct provided also by
Invitrogen that does not target any known vertebrate
gene as described in manufacture’s instruction.
Proliferation assay and cell cycle analysis
Cell viability was measured with a 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colori-
metric assay [55]. In cell cycle analysis, after cell fixation
with 70% ethanol, cells were suspended in 50 μg/ml
Propidium Iodide solution containing 0.1 mg/ml RNase
A and 0.05% Triton X-100 for 40 min at 37℃ and were
analyzed by flow cytometry.
Immunohistochemical analyses
The tissue specimens were obtained from human lymph
nodes filed at the Department of Pathology at Kurume
University. The study of clinical samples was approved
by the local research ethics committee of the Kurume
University. Tissue samples were fixed in 10% formalin
in phosphate buffer and then embedded in paraffin and
analyzed by immunohistochemical methods to deter-
mine ATF3 expression. Images were captured using a
Provis AX80 microscope equipped with an OLYMPUS
DP70 digital camera, and detected using a DP manager
system (Olympus, Tokyo, Japan).
Electroporation
Electroporation was performed with Neon™ transfec-
tion system (Invitrogen). Electroporation parameters for
Jurkat cell were those recommended by Invitrogen.
RNA isolation, Reverse transcriptase (RT)-PCR, real-time
PCR
Total RNAs were extracted using TRIZOL (Invitrogen)
according to the manufacturer’s protocol. Primers for
the ATF3, HBZ,a n dtax genes were described pre-
viously[6,32] The Power SYBR Green PCR Master Mix
(Qiagen, Venlo, Netherlands) was used in real-time PCR
analysis in triplicate with b-actin as an internal control.
In general, the threshold cycle numbers for actin in dif-
ferent cells are very close, and the relative mRNA level
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[Ct (actin)-Ct (gene)],
where Ct is threshold cycle number. Primers were 5’-
TGGAAACCAGGAAGCCTAGC-3’ (sense) and 5’-
GAAATTCGTTTGGCTGGATCAT-3’ (antisense) for
CDC2; 5’-GAATGTCAAGACGAAGTA-3’ (sense) and
5’-ATGAACATATCTGCTCTC-3’ (antisense) for
CCNE2.
Oligonucleotide microarray analysis
RNA processing and hybridization to U133 Plus 2.0
GeneChip microarrays were performed according to the
manufacturer’s protocol (Affimetrix, Santa Clara, CA).
Data were analyzed with the GeneSpring GX 10 soft-
ware (Agilent Technologies, Palo Alto, CA).
Immunoprecipitation (IP) and immunoblotting
Cell lysates were incubated with anti-His-Tag (PM002)
(MBL, Nagoya, Japan), anti-c-myc (clone 9E10) and
anti-FLAG M2 antibodies (Sigma-Aldrich, St Louis,
MO) for 1 hour at 4°C, and immune complexes were
incubated with protein G-sepharose (GE Healthcare, Lit-
tle Chalfont, UK) for 1 hour at 4°C. The following anti-
bodies were used for immunoblot: anti-ATF3 (Santa
Cruz Biotechnologies, Santa Cruz, CA); anti-His-Tag
(PM002) (MBL); anti-FLAG M2 and anti-p53-biotin
(Sigma-Aldrich); peroxidase-conjugated anti-mouse IgG
or anti-rabbit IgG or streptavidin-biotinylated horserad-
ish peroxidase complex (GE Healthcare). To detect
ATF3 using anti-ATF3 antibody, Immuno-enhancer
(Wako, Osaka, Japan) was used.
Serial IP
Cells were lysed in lysis buffer (50 mM Tris-HCl [pH
7.5], 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, and pro-
tease inhibitor cocktail), and incubated for 1 hour at
4°C. For the first IP, after clarification by low-speed cen-
trifugation, the supernatants were incubated with anti-
FLAG M2 Affinity gel (Sigma-Aldrich) for 3 h at 4°C.
The FLAG-agarose beads were then washed with lysis
buffer and the bound proteins were eluted with FLAG
elution buffer (50 mM Tris-HCl, 150 mM NaCl, and 0.5
mg/ml FLAG peptide [Sigma]) for 1 hr at 4°C. For the
second IP, after the FLAG-agarose beads were removed
by centrifugation, the supernatants were incubated with
anti-c-Myc for 1 hr at 4°C.
Additional material
Additional file 1: Figure S1. Identification of candidate genes regulated
by ATF3 expression. Oligonucleotide microarray data for control and
ATF3 KD MT-4 cells were subjected to cluster analysis with the
GeneSpring GX 10 software. Each column represents expression level of
a given gene. Red represents increased expression and green represents
decreased expression relative to the normalized expression of the gene
across all samples.
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